A prospective trial of anti-TNF [tumour necrosis factor]-alpha chimeric monoclonal antibody (infliximab, Remicade) on insulin sensitivity, beta cell function and cardiovascular risk profile in insulin resistant human obesity

Trial Profile

A prospective trial of anti-TNF [tumour necrosis factor]-alpha chimeric monoclonal antibody (infliximab, Remicade) on insulin sensitivity, beta cell function and cardiovascular risk profile in insulin resistant human obesity

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Oct 2016

At a glance

  • Drugs Infliximab (Primary)
  • Indications Insulin resistance; Metabolic syndrome; Obesity
  • Focus Pharmacodynamics
  • Most Recent Events

    • 04 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top